🇺🇸 FDA
Patent

US 10822588

Agents and methods to elicit anti-tumor immune response

granted A61KA61K2039/57A61K2239/38

Quick answer

US patent 10822588 (Agents and methods to elicit anti-tumor immune response) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Nov 03 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
31
CPC classes
A61K, A61K2039/57, A61K2239/38, A61K40/11, A61K40/42